BACKGROUND: Geographic access to NCI-Cancer Centers varies by region, race/ethnicity, and place of residence, but utilization of these specialized centers has not been examined at the national level in the U.S. This study identified determinants of NCI-Cancer Center attendance in Medicare cancer patients. METHODS: SEER-Medicare (Surveillance Epidemiology and End Results) data were used to identify individuals with an incident cancer of the breast, lung, colon/rectum, or prostate from 1998-2002. NCI-Cancer Center attendance was determined based on utilization claims from 1998-2003. Demographic, clinical, and geographic factors were examined in multilevel models. We performed sensitivity analyses for the NCI-Cancer Center attendance definition. RESULTS: Overall, 7.3% of this SEER-Medicare cohort (N = 211,048) attended an NCI-Cancer Center. Travel-time to the nearest NCI-Cancer Center was inversely related to attendance, showing 11% decreased likelihood of attendance for every 10 minutes of additional travel-time (OR = 0.89, 95%CI 0.88-0.90). Receiving predominantly generalist care prior to diagnosis was associated with a lower likelihood of attendance (OR = 0.79, 95%CI 0.77-0.82). The other factors associated with greater NCI-Cancer attendance were later stage at diagnosis, fewer comorbidities, and urban residence in conjunction with African-American race. CONCLUSIONS: Attendance at NCI-Cancer Centers is low among Medicare beneficiaries, but is strongly influenced by proximity and general provider care prior to diagnosis. Other patient factors are predictive of NCI-Cancer Center attendance and may be important in better understanding cancer care utilization.
BACKGROUND: Geographic access to NCI-Cancer Centers varies by region, race/ethnicity, and place of residence, but utilization of these specialized centers has not been examined at the national level in the U.S. This study identified determinants of NCI-Cancer Center attendance in Medicare cancerpatients. METHODS: SEER-Medicare (Surveillance Epidemiology and End Results) data were used to identify individuals with an incident cancer of the breast, lung, colon/rectum, or prostate from 1998-2002. NCI-Cancer Center attendance was determined based on utilization claims from 1998-2003. Demographic, clinical, and geographic factors were examined in multilevel models. We performed sensitivity analyses for the NCI-Cancer Center attendance definition. RESULTS: Overall, 7.3% of this SEER-Medicare cohort (N = 211,048) attended an NCI-Cancer Center. Travel-time to the nearest NCI-Cancer Center was inversely related to attendance, showing 11% decreased likelihood of attendance for every 10 minutes of additional travel-time (OR = 0.89, 95%CI 0.88-0.90). Receiving predominantly generalist care prior to diagnosis was associated with a lower likelihood of attendance (OR = 0.79, 95%CI 0.77-0.82). The other factors associated with greater NCI-Cancer attendance were later stage at diagnosis, fewer comorbidities, and urban residence in conjunction with African-American race. CONCLUSIONS: Attendance at NCI-Cancer Centers is low among Medicare beneficiaries, but is strongly influenced by proximity and general provider care prior to diagnosis. Other patient factors are predictive of NCI-Cancer Center attendance and may be important in better understanding cancer care utilization.
Authors: Michael E Carney; Johnathan M Lancaster; Clyde Ford; Alexander Tsodikov; Charles L Wiggins Journal: Gynecol Oncol Date: 2002-01 Impact factor: 5.482
Authors: Kitaw Demissie; Olalekan O Oluwole; Bijal A Balasubramanian; Omowunmi O Osinubi; David August; George G Rhoads Journal: Ann Epidemiol Date: 2004-03 Impact factor: 3.797
Authors: Kelvin K Pho; Rong Lu; Samantha Gates; Jennifer Cai; Donglu Xie; Yang Xie; Simon J Craddock Lee; David E Gerber Journal: JCO Clin Cancer Inform Date: 2019-02
Authors: Justin A Yu; Kristin N Ray; Seo Young Park; Amanda Barry; Cardinale B Smith; Peter G Ellis; Yael Schenker Journal: J Oncol Pract Date: 2018-11-08 Impact factor: 3.840
Authors: Andrew L Laccetti; Beibei Chen; Jennifer Cai; Samantha Gates; Yang Xie; Simon J Craddock Lee; David E Gerber Journal: J Oncol Pract Date: 2016-10-31 Impact factor: 3.840
Authors: Kelvin Pho; Rong Lu; Samantha Gates; Yang Xie; Simon J Craddock Lee; David E Gerber Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777
Authors: Tracy Onega; Eric J Duell; Xun Shi; Eugene Demidenko; Daniel Gottlieb; David C Goodman Journal: Med Care Res Rev Date: 2009-05-19 Impact factor: 3.929
Authors: David E Gerber; Andrew L Laccetti; Beibei Chen; Jingsheng Yan; Jennifer Cai; Samantha Gates; Yang Xie; Simon J Craddock Lee Journal: J Oncol Pract Date: 2014-07-08 Impact factor: 3.840